Rare Breast Cancer: 933 Adenoid Cystic Carcinomas from the National Cancer Data Base
Autor: | Jon M. Greif, Marlene Zuraek, Soheila Korourian, Lisa Bailey, Nandini Kulkarni, V. Suzanne Klimberg, Christopher M. Pezzi |
---|---|
Rok vydání: | 2013 |
Předmět: |
Oncology
medicine.medical_specialty Adenoid cystic carcinoma medicine.medical_treatment Antineoplastic Agents Breast Neoplasms Kaplan-Meier Estimate Mastectomy Segmental Adenoid Breast cancer Surgical oncology Internal medicine medicine Humans Stage (cooking) Lymph node Neoplasm Staging business.industry Carcinoma Ductal Breast Cancer Middle Aged medicine.disease Carcinoma Adenoid Cystic Hormones medicine.anatomical_structure Receptors Estrogen Chemotherapy Adjuvant Lymphatic Metastasis Female Radiotherapy Adjuvant Surgery Hormone therapy Neoplasm Grading Receptors Progesterone business |
Zdroj: | Annals of Surgical Oncology. 20:2236-2241 |
ISSN: | 1534-4681 1068-9265 |
DOI: | 10.1245/s10434-013-2911-z |
Popis: | Adenoid cystic carcinoma (ACC) is a rare subtype of breast malignancy. Patients with ACC and infiltrating ductal carcinoma (IDC) reported to the National Cancer Data Base from 1998 to 2008 were reviewed for patient age, ethnicity, tumor size, nodal status, American Joint Committee on Cancer TNM Stage, tumor grade, initial treatment, hormone receptor status (for patients from 2004 to 2008), and survival (for patients from 1998 to 2003). A total of 933 patients with ACC and 729,938 with IDC were identified. No differences were found for incidence by race/ethnicity (p = 0.97). The group with ACC was older (median 60 vs. 58 years), had larger tumors (median 18 vs. 16 mm), had more grade 1 tumors (46 vs. 18 %), was less likely to undergo axillary lymph node evaluation (75.9 vs. 96.3 %), had fewer node-positive patients (5.1 vs. 35.5 %), had fewer estrogen receptor–positive tumors (15.4 vs. 75.6 %), had fewer progesterone receptor–positive tumors (13.3 vs. 65.2 %), and underwent breast-conserving surgery more often (69.8 vs. 59.8 %). Chemotherapy was provided less often for ACC (11.3 vs. 46.4 %), as was hormone therapy (9.1 vs. 42.3 %). All of these differences were statistically significant (p |
Databáze: | OpenAIRE |
Externí odkaz: |